← Leaderboards
Cecilia Larocca
Brigham And Women'S Hospital
$3,995,479
Attributed
$3,995,479
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,995,479 · 1
By mechanism
R37$3,995,479 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Oliver Jonas$9,092,029
- Rachael Ann Clark$20,922,246
- Nobuhiko Hata$5,976,509
- Samuel C Mok$7,260,442
- Heather Cody Hazlett$6,380,714
Others in their field
Other Emerging Leaders on “Drug Development”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$256,285,510
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Klaus Romero · Critical Path Institute$88,602,036
Research focus
Drug DevelopmentDrug UsageCutaneous T-Cell LymphomaDrug CandidateDrug ScreeningDrug SensitivityClinical TrialsCutaneousDoseBreast Cancer PatientCombined Modality TherapyCancerousCancer PatientCancer TherapyCancer TypeAntineoplastic AgentsCost EffectiveCellsClinical Trial EnrollmentDevicesClinical DevelopmentClinically RelevantCombinatorialEffective Therapy
Grant awards (6)
Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients$1,155,118
R37 · FY2025 · CA · contact PI
Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients$352,052
R37 · FY2024 · CA · contact PI
Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients$702,007
R37 · FY2023 · CA · contact PI
Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients$294,654
R37 · FY2022 · CA · contact PI
Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients$732,152
R37 · FY2021 · CA · contact PI
Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients$759,496
R37 · FY2020 · CA · contact PI